In tumour cells, elevated levels of mitochondria-bound isoforms of hexokinase (HK-I and HK-II) result in the evasion of apoptosis, thereby allowing the cells to continue proliferating. The molecular mechanisms by which bound HK promotes cell survival are not yet fully understood. Our studies relying on the purified mitochondrial outer membrane protein VDAC (voltagedependent anion channel), isolated mitochondria or cells in culture suggested that the anti-apoptotic activity of HK-I occurs via modulation of the mitochondrial phase of apoptosis. In the present paper, a direct interaction of HK-I with bilayer-reconstituted purified VDAC, inducing channel closure, is demonstrated for the first time. Moreover, HK-I prevented the Ca 2+ -dependent opening of the mitochondrial PTP (permeability transition pore) and release of the pro-apoptotic protein cytochrome c. The effects of HK-I on VDAC activity and PTP opening were prevented by the HK reaction product glucose 6-phosphate, a metabolic intermediate in most biosynthetic pathways. Furthermore, glucose 6-phosphate re-opened both the VDAC and the PTP closed by HK-I. The HK-I-mediated effects on VDAC and PTP were not observed using either yeast HK or HK-I lacking the N-terminal hydrophobic peptide responsible for binding to mitochondria, or in the presence of an antibody specific for the N-terminus of HK-I. Finally, HK-I overexpression in leukaemia-derived U-937 or vascular smooth muscle cells protected against staurosporineinduced apoptosis, with a decrease of up to 70 % in cell death. These results offer insight into the mechanisms by which bound HK promotes tumour cell survival, and suggests that its overexpression not only ensures supplies of energy and phosphometabolites, but also reflects an anti-apoptotic defence mechanism.
INTRODUCTION
Cancer cells are characterized by a high rate of glycolysis, which serves as their primary energy-generating pathway [1, 2] . The molecular basis of this high rate of glycolysis involves a number of genetic and biochemical events [2] , including overexpression of mitochondrial-bound isoforms of hexokinase (HK-I and HK-II) [2] [3] [4] . The bound enzyme is less susceptible to inhibition by its product, glucose 6-phosphate (G-6-P), a metabolic intermediate precursor in most biosynthetic pathways [5] .
Accumulating evidence indicates that HK (both HK-I and HK-II) plays a pivotal role in cancer by promoting cell growth and survival [6, 7] . Recent studies [8] indicate that, in malignant cancer, HK-II not only improved the cell's energy supply, but also protected against cell death. HK-II has also been shown to inhibit Bax-induced cytochrome c release and apoptosis in HeLa cells [7] . It has also been proposed that elevated binding of HK-I and/or HK-II to mitochondria in tumour cells is due to an increase in the expression of the VDAC (voltage-dependent anion channel) [9] .
VDAC, an integral protein of the mitochondrial outer membrane also known as mitochondrial porin, is a large channel that transports anions, cations [10, 11] , Ca 2+ [12] , adenine nucleotides [13] and other metabolites [14] into and out of mitochondria. VDAC is also believed to be a constituent of the mitochondrial PTP (permeability transition pore). Current models suggest that a PTP is formed at contact sites between the inner and outer membranes by association of VDAC in the outer membrane with the ANT (adenine nucleotide translocator) in the inner membrane, cyclophilin D in the matrix, and possibly other proteins [15, 16] . Regulated opening of the PTP leads to a rapid loss Abbreviations used: ANT, adenine nucleotide translocator; CsA, cyclosporin A; GFP, green fluorescent protein; G-6-P, glucose-6-phosphate; HK, hexokinase; LDAO, lauryl(dimethyl)amine oxide; PLB, planar lipid bilayer; PTP, permeability transition pore; VDAC, voltage-dependent anion channel. 1 To whom correspondence should be addressed (e-mail vardasb@bgumail.bgu.ac.il).
of mitochondrial membrane potential, organellar swelling and release of the apoptogenic protein cytochrome c. This, in turn, activates caspases (death-driving proteolytic proteins) [17] and leads to apoptotic cell death [17] [18] [19] . HK-I and HK-II share high functional similarity and differ only in tissue distribution [20] . Both isoforms interact via a hydrophobic 15-amino-acid sequence in their N-terminal region with mitochondrial VDAC [21] [22] [23] . The occurrence of an interaction between HK-I and VDAC is supported by various pieces of evidence: the enrichment of both HK-I and VDAC at the contact site fraction [23] , binding of HK-I to VDAC reconstituted into liposomes [24] , and co-purification of HK-I with the VDAC-ANT complex [23] . However, none of the findings demonstrated a direct interaction of HK-I with VDAC; nor did they reveal the exact molecular mechanism of this interaction.
Here we demonstrate that HK-I interacts with isolated mitochondria, and prevents the opening of the PTP and PTP-mediated cytochrome c release. Moreover, HK-I binds directly to bilayerreconstituted VDAC and induces closure of its channel. These results suggest that HK-I, by interacting with VDAC, prevents key events in mitochondria-mediated apoptosis.
Sigma (St. Louis, MO, U.S.A.). Cibacron Blue-agarose was purchased from Amersham Biosciences (Uppsala, Sweden), and 45 Ca 2+ was purchased from NEN ® Life Science Products (Boston, MA, U.S.A.). n-Octyl β-D-glucopyranoside was obtained from Bachem AG, and LDAO [lauryl(dimethyl)amine oxide] was obtained from Fluka. Hydroxyapatite (Bio-Gel HTP) was purchased from Bio-Rad Laboratories (Hercules, CA, U.S.A.), and Celite was from BDH (Poole, Dorset, U.K.).
Monoclonal anti-VDAC antibodies raised against the N-terminal region of 31HL human porin [25] 
Mitochondrial preparation
Mitochondria were isolated from rat liver using published procedures [26] .
Ca

2+ accumulation
Ca 2+ uptake by freshly prepared rat liver mitochondria (0.5 mg/ ml) was assayed for 1-20 min at 30
• C in the presence of 225 mM mannitol, 75 mM sucrose, 120 µM CaCl 2 (containing 3 × 10 4 c.p.m./nmol 45 Ca 2+ ), 5 mM Hepes/KOH, 5 mM succinate and 0.1 mM P i , pH 7.0. 45 Ca 2+ uptake was terminated by rapid Millipore filtration followed by a wash with 5 ml of 150 mM KCl [12] .
Mitochondrial swelling
Ca
2+ -induced large-amplitude mitochondrial swelling was assayed in freshly prepared mitochondria under the same conditions as for Ca 2+ accumulation, except that the temperature was 24
• C. CsA-sensitive mitochondrial swelling was initiated by the addition of Ca 2+ (0.2 mM) to the sample. Absorbance changes at 520 nm were monitored every 15-20 s with an Ultraspec 2100 spectrophotometer.
Release of cytochrome c
Mitochondria (0.5 mg/ml) were incubated with or without 1 unit/ ml HK-I in a solution containing 150 mM KCl, 25 mM NaHCO 3 , 5 mM succinate, 1 mM MgCl 2 , 3 mM KH 2 PO 4 and 20 mM Hepes, pH 7.4 [8] . Swelling was monitored after the addition of 200 µM Ca 2+ , and following complete swelling the samples were centrifuged and mitochondrial pellets (25 µg) or supernatant (40 µl) were subjected to SDS/PAGE and Western blot analysis using monoclonal antibodies against cytochrome c.
Purification, proteolytic treatment and activity of rat brain HK-I Rat brain HK-I was purified according to Wilson [27] . Briefly, crude brain mitochondria containing tightly bound HK-I were incubated with 1.2 mM G-6-P and 0.5 mM K-EDTA to release the enzyme into the soluble fraction. Further purification of HK-I was achieved by affinity chromatography on Cibacron Blue-agarose (Pharmacia). The purified enzyme was concentrated and washed in 0.5 mM K-EDTA, 10 mM glucose, 1 mM dithiothreitol and 10 mM K-Hepes, pH 7.8, using an Amicon device and a 50 000 Da molecular mass cut-off membrane (Spectrum; type C). The concentrated enzyme (up to 1 mg/ml; 30-60 units/mg) was frozen in liquid nitrogen and stored at − 80
• C until use. For proteolytic treatment, HK-I was incubated for 1 h on ice with trypsin or chymotrypsin at a protease/HK-I ratio of 1:4 (w/w) in a solution containing 10 mM glucose, 5 mM Mg-Hepes and 20 mM K-Hepes, pH 7.8. Proteolysis was terminated by addition of a 5-fold excess (w/w) of trypsin inhibitor or 0.5 mM PMSF. In the case of chymotrypsin treatment, removal of the N-terminal hydrophobic peptide of HK-I was confirmed by Western blot analysis using a specific monoclonal antibody.
HK-I activity was measured spectrophotometrically at room temperature at 340 nm by coupling NADH formation to the production of G-6-P by HK-I and its oxidation by G-6-P dehydrogenase. The reaction mixture (1 ml) contained 4 mM MgHepes, 1 mM K-EDTA, 0.6 mM NAD + , 10 mM glucose, 1 mM ATP, 1 mg/ml BSA and 20 mM K-Hepes, pH 7.8. A 100-fold excess of G-6-P dehydrogenase over HK-I was employed.
Binding of rat brain HK-I to mitochondria
Mitochondria (0.5-2 mg/ml) were incubated on ice for 1 h with HK-I (0-2 unit/ml) in 0.1 ml of iso-osmotic medium supplemented with 5 mM Mg-Hepes, pH 7.8, and 1 mg/ml BSA. Soluble and mitochondria-bound HK-I fractions were separated and analysed for free and bound HK-I activity respectively [28] . HK-I binding was defined as the percentage activity present in the bound fraction relative to the total activity in the bound and free fractions combined. In some cases, HK-I binding was assayed under conditions of mitochondrial swelling.
Protein determination
Mitochondrial protein was determined by the Biuret method [29] , while HK protein concentration was determined according to Bradford [30] , using ovalbumin as a standard.
VDAC purification
VDAC was extracted from mitochondria with 3 % Triton X-100 and purified using chromatography on hydroxyapatite and Reactive Red-agarose in the presence of 0.3 % Triton X-100 [31] . For the study of the interaction of HK-I with VDAC, a novel procedure for the purification of VDAC using the detergent β-octyl glucoside was developed. Briefly, rat liver mitochondria (200 mg of protein) were incubated for 30 min at 0
• C (at 5 mg/ml) in a solution containing 10 mM Tris, pH 7.0, 0.15 mM PMSF, 0.5 µg/ml leupeptin and 0.05 % LDAO. After centrifugation at 44 000 g for 20 min, the supernatant was discarded and the pellet was resuspended at 5 mg/ml in the above solution containing 2 % LDAO. After centrifugation at 44 000 g for 30 min, the LDAOextracted VDAC was applied to a dry hydroxyapatite/celite (2:1, w/w) column (0.08 g/mg of protein) and eluted with a buffer containing 10 mM Tris, pH 7.4, 50 mM NaCl, 20 mM sodium phosphate and 2 % LDAO. The VDAC-containing fractions (identified by Coomassie Blue staining) were collected, diluted 5-fold with 10 mM Tris, pH 7.4, and loaded on to a CM-cellulose column pre-equilibrated with 10 mM Tris, pH 7.4, and 0.5 % noctyl β-D-glucopyranoside. The loaded column was then washed with the same equilibration buffer, and VDAC was eluted with the same buffer containing 0.4 M NaCl.
VDAC recording and analysis
Reconstitution of the purified VDAC into a PLB (planar lipid bilayer), single channel current recording and data analyses were carried out as described previously [12] . Briefly, a PLB was prepared from soybean asolectin dissolved in n-decane (50 mg/ ml). Purified VDAC (approx. 1 ng) was added to the chamber defined as the cis side. After one or a few channels were inserted into the PLB, excess protein was removed by washing the cis chamber with 20 vol. of solution to prevent further incorporation. Currents were recorded under a voltage clamp using a Bilayer Clamp BC-525B amplifier (Warner Instruments, Hamden, CT, U.S.A.). Currents were measured with respect to the trans side of the membrane (ground). The currents were low-pass-filtered at 1 kHz using a Bessel filter (Frequency Devices, Haverhill, MA, U.S.A.), and digitized on-line using a Digidata 1200-interface board and PCLAMP 6 software (Axon Instruments Inc., Union City, CA, U.S.A.).
Gel electrophoresis and immunoblot analyses
SDS/PAGE was performed according to Laemmli [32] and gels were stained with Coomassie Brilliant Blue. For immunostaining, the membranes were blocked with 5 % (w/v) non-fat dry milk and 0.1 % Tween-20 in Tris-buffered saline, incubated with monoclonal anti-VDAC antibodies (1:7000) or anti-HK-I antibodies (1:2000) , and then with alkaline phosphatase-conjugated anti-mouse IgG or horseradish peroxidase-conjugated anti-mouse IgG as a secondary antibody (1:10 000). Using the former, the coloured reaction product was developed with 5-bromo-4-chloro-3-indolyl phosphate and Nitro Blue Tetrazolium, while a Super Signal West Pico kit for an enhanced chemiluminiscent substrate (Pierce, Rockford, IL, U.S.A.) was used for the detection of horseradish peroxidase.
Tissue culture
The U-937 human monocytic cell line was grown under an atmosphere of 95 % air/5 % CO 2 in RPMI 1640 supplemented with 10 % (v/v) fetal calf serum, 1 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. Exponentially growing U-937 cells were resuspended in RPMI 1640 supplemented with 10 % fetal calf serum and 1 mM L-glutamine at a concentration of 2.5 × 10 7 cells/400 µl. The vascular smooth muscle cell line was grown under the same conditions as described for U-973 cells, except that the medium was minimum essential medium. Transfection with the mammalian expression vectors pEGFP, pcDNA3 or pcDNA3-HK-I (provided by Dr J. E. Wilson, University of Michigan) was performed by electroporation with a single pulse from a Bio-Rad Micropulser II with a capacitance extender unit (200V, 950 µF). Transfection efficiencies were 68-72 %, as assessed by GFP (green fluorescent protein) expression. Transfected cells were incubated on ice for 10 min before and after transfection, and then resuspended in 20 ml of RPMI 1640 supplemented with 10 % fetal calf serum, 1 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. The cells were then grown for 72 h prior to the induction of apoptosis by the addition of 1.25 µM staurosporine.
Treatment of cells
Cells were plated at a density of 5.4 × 10 4 cells/cm 2 in 24-well plate, washed once with PBS and placed in serum-free medium. The cells were then either left untreated or treated with staurosporine (1.25 µM) to induce apoptosis. Cells were analysed for viability after 3, 5 and 7 h.
Acridine Orange/ethidium bromide staining of cells
To determine cell viability, cells were subjected to Acridine Orange/ethidium bromide staining. Cells were centrifuged at 1500 g for 5 min at room temperature and then resuspended in a 25 µl of medium, to which 2 µl of a solution containing 100 µg/ ml Acridine Orange and 100 µg/ml ethidium bromide in PBS was added. The cells were then visualized by fluorescence microscopy (Olympus BX60, equipped with a CCD camera), using a blue filter.
RESULTS
HK-I interacts specifically with VDAC to induce channel closure
Highly purified (> 98 %) mitochondrial VDAC (see Figure 1C) , isolated from liver mitochondria using CM-cellulose and β-octyl glucoside, was reconstituted into a PLB and its channel activity was studied under voltage-clamp conditions [12, 33] . Current passing through the VDAC in response to voltages stepped from a holding potential of 0 mV to the potentials indicated in each current trace was recorded prior to the addition of HK-I. At relatively small membrane potentials (− 10 mV), the conductance remained constant for up to 120 min of recording ( Figure 1 ). However, upon addition of purified HK-I, the open channel was stabilized in its low-conducting state ( Figure 1A, I ). HK-Ipromoted VDAC closure was observed at all voltages tested, with the VDAC adopting a constant conductance regardless of the voltage gradient applied ( Figure 1B) . HK-I modified VDAC conductance only when added to the cis side of the bilayer in which VDAC was reconstituted, indicating, as expected, that HK-I interacts with the cytosolic face of VDAC [22] .
The specificity of the interaction of HK-I with VDAC was demonstrated by several observations. Yeast HK had no effect on VDAC conductance ( Figure 1A, III) . In addition, HK-I subjected to chymotryptic ( Figure 1A , II) or tryptic (results not shown) digestion failed to modify VDAC conductance. It has been shown that treatment of HK-I and HK-II with trypsin or chymotrypsin results in removal of the N-terminal hydrophobic peptide of HK-I that is responsible for its binding to mitochondria [21] . Indeed, protease-treated HK-I did not cross-react with a specific monoclonal antibody against the HK-I N-terminus (Figure 1C) , indicating the requirement of the HK-I N-terminal region for its interaction with VDAC. Furthermore, HK-I was able to close the VDAC in the presence of yeast HK ( Figure 1A, III) or chymotrypsin-treated HK-I ( Figures 1A, II and 1A, III) .
The effect of HK-I on VDAC was reversed by the HK reaction product G-6-P, a central metabolic intermediate precursor in biosynthetic pathways. Furthermore, addition of G-6-P led to the re-opening of channels closed by HK-I ( Figure 1A, III) , supporting a reversible interaction of HK-I with VDAC.
HK-I prevents opening of the PTP
Opening of the mitochondrial PTP is thought to be one of the checkpoints that mediate cell entry into apoptosis [15] [16] [17] [18] [19] [34] [35] [36] . Since VDAC is a proposed component of the PTP, the effects of HK-I on PTP opening, as monitored by Ca 2+ accumulation and swelling of energized mitochondria, and by PTP-mediated release of cytochrome c, were addressed. When freshly prepared mitochondria were allowed to generate a membrane potential, transient Ca 2+ accumulation was observed (Figure 2A ). This suggests that mitochondria undergo a permeability transition and lose accumulated Ca 2+ via the PTP [12, 15, 18] . Addition of HK-I prior to PTP induction, or even after Ca 2+ accumulation had reached its peak, yet before PTP activation, prevented the release of accumulated Ca 2+ (Figure 2A ). In the presence of HK-I, mitochondrial swelling, as monitored by the change in absorbance following Ca 2+ addition, was also prevented ( Figure 2B ).
Specificity of the effect of HK-I in preventing PTP opening and cytochrome c release
The specificity of the effect of HK-I on PTP opening was reflected by several findings. HK-I-mediated inhibition of PTP opening was prevented by an antibody specific to the N-terminus of HK-I ( Figure 3A) . The failure of non-binding species of HK, such as yeast HK or trypsin-or chymotrypsin-treated HK-I ( Figure 3B ), to prevent PTP opening also confirmed the specificity of the HK-I effect, and the requirement of the N-terminal region of HK-I for its interaction with VDAC. Upon induction of the PTP, cytochrome c was released from mitochondria (as revealed by Western blot analysis). HK-I, however, inhibited this release ( Figure 3C ). These effects of HK-I are similar to those of CsA, a well known inhibitor of the PTP (Figures 2B and 3C) . Indeed, the CsA-sensitive mitochondrial swelling, transient Ca 2+ accumulation and release of cytochrome c, events that reflect PTP opening and are almost universal features of apoptotic cell death [20] , were all inhibited specifically by HK-I.
Correlation between HK-I binding and prevention of PTP opening and its susceptibility to G-6-P
The binding of HK to mitochondria is of potential benefit, since bound HK can exclusively utilize mitochondrially synthesized ATP, and is less susceptible to inhibition by its product G-6-P [5] . As shown in Figure 4 , G-6-P prevented the closure of the PTP by HK-I in a concentration-dependent manner. Moreover, G-6-P was able to re-open a PTP closed by HK-I (Figure 4B ). Thus G-6-P was able to re-open not only HK-I-closed bilayer-reconstituted VDAC (Figure 1 ), but also HK-I-closed PTP, suggesting a reversible interaction of HK-I with VDAC, and thereby with PTP.
The concentrations of G-6-P required for the prevention of PTP closure by HK-I were approx. 50-fold higher than those required for the inhibition of soluble HK-I activity (IC 50 values of 5 and 0.1 mM respectively; Figure 4C ). Thus, in agreement with earlier studies [5] , binding of HK-I to mitochondria conferred resistance to G-6-P.
Since our results suggested that a protein-protein interaction between HK-I and VDAC serves to modulate PTP opening, the correlation between HK-I binding to mitochondria and inhibition of PTP opening was analysed. Indeed, HK-I binding to isolated mitochondria and the subsequent prevention of PTP opening (as a function of HK-I concentration) were well correlated. Both interactions showed strong positive co-operativity ( Figure 4D ). This high co-operativity is thought to reflect the assembly of HK-I or HK-II tetramers prior to, or during, mitochondrial binding [37, 38] , and could suggest that modulation of the PTP by HK-I requires oligomerization of the former before or during its interaction with VDAC.
Effects of known PTP modulators on the prevention of PTP opening by HK-I
The effects of PTP ligands on its modulation by HK-I are demonstrated in Figure 5 . Atractyloside, a known inhibitor of the ANT (a proposed component of the PTP [39] ) and promoter of PTP opening, did not prevent HK-I-induced PTP closure when added either before of after HK-I addition ( Figure 5A ). This indicates Figure 4 Modulation by G-6-P of HK-I binding to mitochondria and prevention of PTP opening (A) PTP opening (mitochondrial swelling) was assayed in the absence (᭹) or the presence of HK-I (1 unit/ml) and the indicated concentrations of G-6-P (in mM). (B) PTP opening was assayed in the presence of HK-I; at the indicated time, G-6-P (1.5 mM) was added, and the re-opening of the PTP was followed. (C) The data in (A) were re-plotted as the percentage of PTPs closed as a function of G-6-P concentration (᭹). Control (100 %) represents completely closed PTP (in the presence of HK-I), and the degree of PTP closure in the presence of both HK-I and G-6-P was determined after 15 min. In the presence of HK-I, half-maximal PTP opening was obtained at 5 mM G-6-P (i.e. IC 50 = 5 mM). Inhibition of soluble HK-I activity by different concentrations of G-6-P is also presented (᭺; IC 50 that HK-I binding to the VDAC determines the closed/open state of the PTP. Finally, as shown previously [40, 41] , the presence of ADP or ATP delayed PTP opening by approx. 5 to 10 min (Figure 5B) . HK-I, in the presence of either nucleotide, stabilized the PTP in the closed conformation, and no PTP opening was observed even after 40 min. 
Expression of HK-I in cell culture prevents staurosporine-induced apoptosis
Since cancer cells are characterized by overexpression of HK-I and HK-II [2] , we tested whether HK-I overexpression in leukaemia-derived U-937 cells would suppress apoptosis induced by staurosporine. Accordingly, U-937 cells were transfected with plasmids containing GFP or HK-I, or with no insert. Apoptosis was then induced in the different cells by exposure to staurosporine ( Figure 6 ). Upon exposure of control or plasmidtransfected cells to staurosporine for 5 or 7 h, 50 % and 80 % respectively of the cells underwent apoptosis, whereas 12 % of the cells not exposed to staurosporine died. When U-937 cells were transformed to express HK-I, a decrease in the degree of staurosporine-induced apoptotic cell death of approx. 67 % was observed after 5 h, with a decrease of 46 % after 7 h ( Figure 6E ). Taking into account the fact that only approx. 70 % of the cells were transfected, the resistance to staurosporine-induced apoptosis in cells overexpressing HK-I was estimated to be approx. 95 % and 66 % after 5 and 7 h respectively of exposure to staurosporine. In such cells, HK-I levels in the mitochondrial fraction were increased 5-6-fold relative to those in control cells, and in comparison with the levels of VDAC ( Figure 6F ).
The anti-apoptotic effect of HK-I overexpression was also observed in a non-cancer vascular smooth muscle cell line, where apoptotic cell death was decreased by approx. 69 % and 50 % after 5 and 7 h respectively of exposure to staurosporine (Figure 6G) .
DISCUSSION
In the present study, we have characterized the modulation of the mitochondrial phase of apoptosis by HK-I using purified HK-I, purified VDAC, isolated mitochondria and HK-I-overexpressing tumour-derived cells in culture. Our results show that purified HK-I interacts directly with purified VDAC reconstituted into a PLB, inducing channel closure. Interaction of HK-I with mitochondria prevented the opening of the PTP as well as the accompanying release of cytochrome c. These findings provide clear evidence that HK-I interacts directly with the VDAC, preventing PTP opening and thereby the mitochondrial phase of apoptosis.
Mitochondria are recognized as the site of regulation of the execution of cell death initiation, especially apoptosis [16] [17] [18] [19] [34] [35] [36] 42] . The mitochondrial phase of apoptosis involves the opening of the PTP and the selective release of pro-apoptotic proteins responsible for apoptotic cell death from the inter-membrane space [15, 18, [43] [44] [45] . The molecular composition and regulation of the PTP are yet not fully understood. Current models suggest that the VDAC and ANT, embedded in the mitochondrial outer and inner membranes respectively, are constituents of the PTP [15, 18, 44] . Whereas HK-I or HK-II has no physical contact with the ANT, it binds to the VDAC, as demonstrated in this and other studies [24, 46] . It should be noted, however, that attempts to demonstrate physical interactions between HK-I or HK-II and the VDAC by cross-linking have failed so far. This may reflect the complex and dynamic nature of the interaction. Still, the results presented here provide strong evidence for the VDAC being part of the PTP, and for the modulation of the PTP through the interaction of HK-I with the VDAC, leading to its closure.
Ultimately, closure of the PTP-associated VDAC by HK-I through direct protein-protein contacts would prevent opening of the PTP from and release of the pro-apoptotic protein cytochrome c (Figures 2-5) , thereby blocking the gateway to apoptosis. This proposal was confirmed at the cellular level, whereby overexpression of HK-I in the tumour-derived cell line U-973 or in vascular smooth muscle cells suppressed staurosporine-induced apoptotic cell death by approx. 68 % (or by approx. 97 % when taking into account a cell transfection efficiency of 70 %) (Figure 6) . A decrease in apoptotic cell death and an increase in cell proliferation have also been reported following HK-II expression in NIH-3T3 [6] and Rat 1a [47] cell lines.
Binding of HK-I to the mitochondria and modulation of the PTP showed high co-operativity ( Figure 4D ), consistent with previous results on HK-I binding to mitochondria. This can be interpreted as reflecting the formation of HK-I tetramers prior to, or during, binding to mitochondria [28, 37] . Interestingly, oligomerization of Bax, a pro-apoptotic protein, before its interaction with mitochondria (most likely with the VDAC [48] ), as well as the ability of HK-II to hinder such an interaction [8] , have been reported. These effects of HK-I and HK-II point to the central role played by these enzymes in protecting cells from death via their interaction with the VDAC and modulation of the mitochondrial phase of apoptosis.
By binding to the VDAC, HK gains preferential access to mitochondrially generated ATP [2] , thereby leading to greatly increased rates of aerobic glycolysis [49] . Aerobic glycolysis provides a number of metabolic intermediates used in biosynthetic reactions that provide building blocks for fatty acid synthesis, DNA replication and protein production. The increased levels of G-6-P generated by the enhanced amount of HK-I supports NADPH production and, thereby, many other biosynthetic reactions, including those involved in antioxidant defence [50] . Thus the expression of high levels of HK-I or HK-II in transformed cells was interpreted as an adaptation to maintain the heavy energetic demands of such cells. Our studies, however, also demonstrate that HK-I prevented PTP opening by direct interaction with the VDAC, stabilizing it in the closed state, even when one of the other major components of the PTP, i.e. the ANT, was stabilized by atractyloside in the open conformation ( Figure 5) .
The results presented here provide new insight into the mechanism whereby mitochondria-bound HK promotes tumour cell growth and survival. We propose that overexpression of HK-I in malignant cells serves to ensure a supply of energy and phosphometabolites for the proliferating cell, and also reflects a defence mechanism. In this defence mechanism, HK-I prevents apoptotic cell death by inhibiting opening of the PTP and release of the proapoptotic cytochrome c, as well as by interfering with the ability of the pro-apoptotic Bax protein to bind to mitochondria and induce release of cytochrome c [8] , thus encouraging cell survival [7] .
Regardless of the nature of regulation of the PTP, VDAC, as a component of the PTP, offers a suitable target for pharmacological intervention designed to correct abnormalities associated with dysregulation of mitochondrial homoeostasis observed under conditions of oxidative stress, toxaemia or apoptosis. Furthermore, HK, as recently suggested [2] , is a key player in the growth and survival of many types of cancer, and hence represents an ideal prospect for therapeutic intervention in view of its interaction with and modulation of VDAC activity, as demonstrated here.
